| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 17.2 Billion |
| Market Size in 2026 | USD 19.5 Billion |
| Market Size by 2032 | USD 43.5 Billion |
| Projected CAGR | 14.2% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Consolidated |
Explore the market potential with our data-driven report
The aortic valve market size was USD 17.2 billion for 2025, and it will grow by 14.2% during 2026–2032, to reach USD 43.5 billion by 2032.
The market growth is driven by the increasing prevalence of aortic stenosis and aortic regurgitation, particularly among the aging population. Additionally, the growing adoption of transcatheter aortic valve replacement as a less invasive and clinically validated alternative to surgical aortic valve replacement is further accelerating market expansion.
Sutureless valve platforms, next-generation tissue prostheses incorporating anti-calcification technologies, and progressively expanding procedural indications are collectively reinforcing market momentum across both high-income and emerging healthcare economies. The World Health Organization projects that the global population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion by 2030, directly amplifying the patient pool for aortic valve interventions at an accelerating pace.
The clinical boundaries of transcatheter aortic valve replacement have expanded dramatically over the past decade, fundamentally reshaping the treatment paradigm for aortic valve disease and, by extension, the global market. This evolution is underpinned by successive generations of transcatheter valve platforms, including self-expanding, balloon-expandable, and mechanically-expanded devices, that have achieved significant reductions in paravalvular leak, conduction abnormalities, and procedural stroke rates. In England in 2022/23, 7,697 transcatheter aortic valve implantation procedures were performed, with TAVI rates reaching approximately 136 procedures per million population compared with about 60 SAVR procedures per million population, indicating considerably higher adoption of catheter-based intervention where capacity exists.
Additionally, improvements in delivery system profiles have enabled transfemoral access in the vast majority of cases in developed markets. In the United States, transfemoral access accounted for approximately 95% of all TAVR procedures in 2023, according to national registry data, reducing reliance on alternative access routes and contributing to shorter hospital stays in many centers.
The accelerating aging of the global population represents the most significant structural driver of the aortic valve market. According to the WHO, cardiovascular diseases were responsible for an estimated 19.8 million deaths worldwide in 2022, highlighting the substantial global burden of cardiovascular disease and the continued need for advanced interventional cardiac therapies. As life expectancy rises across both high- and middle-income nations, the prevalence of calcific aortic valve disease increases proportionally, reinforcing long-term intervention demand.
Global Burden of Disease 2021 data indicate that global calcific aortic valve disease cases increased from 4.97 million in 1992 to 13.32 million in 2021, representing a 167.74% rise over three decades. In addition, the age-standardized prevalence rate increased from 130.82 to 158.35 per 100,000, and global incidence rose by approximately 150.7% during the same period, indicating that disease burden has risen even after adjusting for demographic structure.
As the addressable patient population expands, regulatory developments are further supporting procedural growth. In August 2025, Medtronic plc received U.S. FDA approval for an expanded redo-TAVR indication of its Evolut systems, broadening eligibility among previously treated patients and reinforcing sustained volume expansion in transcatheter interventions.
A structural market expansion pathway exists across Asia Pacific, Latin America, and the Middle East & Africa, where large and growing populations with significant aortic valve disease burden remain dramatically underserved relative to high-income markets. Recent analyses based on Global Burden of Disease 2021 data estimate that non-rheumatic valvular heart disease accounted for approximately 28.4 million prevalent cases and 2.21 million new incidence cases globally in 2021, resulting in 181,078 deaths and 3.24 million disability-adjusted life years, with a disproportionate share of burden concentrated in developing regions. China alone accounted for approximately 3.28 million prevalent cases in 2021, underscoring the scale of structural heart disease in large emerging economies.
In these regions, the combination of historically limited cardiac catheterization laboratory infrastructure, inadequate reimbursement frameworks, and restricted access to trained TAVR operators has left millions of eligible patients without access to guideline-recommended valve replacement therapy. As governments in China, India, Brazil, Saudi Arabia, and across Southeast Asia invest in cardiac care infrastructure expansion and progressively extend national health insurance coverage to include transcatheter valve procedures, these markets represent a substantial volume expansion opportunity for both global manufacturers and domestic device innovators.
The tissue/biological category holds the largest market share, of 70%, in 2025, and it will have the highest CAGR, of 14.4%, due to its strong alignment with the dominant patient demographic and evolving procedural trends. Severe aortic stenosis predominantly affects the elderly population, and according to the National Center for Biotechnology Information, approximately 2–3% of individuals over the age of 65 are affected globally. In this age group, tissue valves are generally preferred because they typically do not require lifelong anticoagulation therapy, thereby reducing bleeding risks and improving overall quality of life. Additionally, the rapid global expansion of transcatheter aortic valve replacement, which exclusively utilizes bioprosthetic valves, has further strengthened demand.
The valve types analyzed in this report are:
The sutured category holds the largest market share, of approximately 75%, in 2025, driven by its established standard status in conventional SAVR and strong surgeon familiarity. Sutured valves benefit from decades of accumulated clinical evidence, widespread surgeon familiarity, highly predictable hemodynamic performance, and broad compatibility across patient anatomies and annulus sizes. Surgical aortic valve replacement is broadly covered under Medicare’s established inpatient reimbursement framework for medically necessary cardiac surgery, supporting stable procedural volumes across eligible patient populations.
The sutureless category will have the highest CAGR, of 14.5%, driven by its strong procedural advantages in minimally invasive SAVR contexts. Sutureless platforms, including LivaNova's Perceval Plus and Edwards' Intuity Elite, eliminate the need for traditional annular suture placement, materially reducing aortic cross-clamp time and cardiopulmonary bypass duration, which translates into superior outcomes for high-risk and elderly patients. The European Society of Cardiology 2024 revised guidelines recommend sutureless and rapid-deployment valves as preferred options in minimally invasive SAVR contexts given their demonstrated procedural efficiency benefits.
The suture types analyzed in this report are:
The open heart surgery category holds the largest market share, of 75%, in 2025, driven by its established gold-standard status for complex and younger patients and the widespread availability of conventional SAVR programs across global hospital networks. According to the Society of Thoracic Surgeons National Database, approximately 18,792 isolated surgical aortic valve replacement procedures were performed in the United States in 2023.
The minimally invasive surgery category will have the highest CAGR, of 14.6%, due to continued TAVR expansion into new patient populations and the growing use of sutureless SAVR via minithoracotomy. Within MIS, transfemoral aortic valve replacement constitutes the dominant sub-segment, given its access simplicity, same-day or next-day discharge potential, and extensive real-world evidence base. The Centers for Medicare & Medicaid Services expanded national coverage for TAVR progressively to include all surgical risk categories, establishing the reimbursement foundation that supports MIS procedure volume growth across U.S. hospital systems.
The procedures analyzed in this report are:
The hospitals category holds the largest market share in 2025, driven by the structural concentration of advanced cardiac infrastructure, including hybrid operating rooms, cardiac catheterization laboratories, cardiopulmonary bypass capability, and cardiac intensive care units, which are essential for both surgical aortic valve replacement and transcatheter aortic valve replacement. Additionally, regulatory frameworks such as the procedural and programmatic requirements established by the Centers for Medicare & Medicaid Services mandate that TAVR be performed in qualified hospital-based structural heart programs, reinforcing hospital dominance. The continued volume of open-heart surgeries for complex anatomies and concomitant procedures further sustains hospitals as the primary care setting for aortic valve interventions globally.
The ASCs category will have the highest CAGR, as clinical evidence supporting same-day discharge TAVR in low-risk patients continues to accumulate and reimbursement policies adapt. The Medicare Payment Advisory Commission reported that approximately 6,100 ASCs served nearly 3.3 million Medicare fee-for-service beneficiaries in 2022, with total ASC service spending reaching approximately USD 6.1 billion, reflecting a broad industry trend toward outpatient care delivery that is now extending into select structural heart procedures.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, supported by the strong concentration of TAVR-capable heart teams across U.S. tertiary cardiac centers and a favorable reimbursement environment under CMS coverage determinations. The region’s leadership is further reinforced by the presence of major aortic valve manufacturers, including Edwards Lifesciences, Medtronic, and Abbott. The U.S. structural heart ecosystem includes more than 800 TAVR-capable hospital programs, with the STS/ACC TVT Registry reporting 838 active TAVR sites in 2023. According to the STS/ACC TVT Registry, 383,030 patients underwent TAVR procedures in the United States between January 2020 and March 2024, underscoring substantial procedural adoption across the region.
In March 2024, Medtronic plc received U.S. FDA approval for its Evolut FX+ transcatheter aortic valve replacement system, featuring enhanced coronary access design to facilitate future coronary interventions, reinforcing competitive innovation within the U.S. structural heart market. The U.S. patient pool for TAVR expanded in May 2025 following FDA approval of the SAPIEN 3 family of transcatheter heart valves by Edwards Lifesciences for use in selected patients with asymptomatic severe aortic stenosis, broadening the indication beyond previously symptomatic-only cases for that platform. Moreover, Canada contributes complementary growth, supported by Health Canada's progressive approval framework for transcatheter devices and a robust publicly funded cardiac surgery infrastructure.
Asia-Pacific will have the highest CAGR, of 14.3%, driven by its rapidly aging population across China, Japan, India, and South Korea. This expansion is supported by increasing healthcare infrastructure investment, broader insurance coverage for cardiac procedures, and a strengthening domestic medical device manufacturing ecosystem. China represents the largest country market within the region, with more than 310 million people aged 60 years and above as of the end of 2024, accounting for 22% of the national population, a demographic trend that positions China as home to one of the fastest-growing elderly populations worldwide. Japan contributes significantly through its advanced cardiac care network and one of the world's oldest population structures, with approximately 29% of its population aged 65 years or older, one of the highest proportions globally.
The World Health Organization projects that the global population aged 80 years or older will triple between 2020 and 2050, reaching 426 million, with Asia Pacific bearing a disproportionately large share of this demographic expansion, creating sustained long-term demand for aortic valve interventions.
India is the fastest-growing country market within Asia Pacific for aortic valve devices, driven by a large and underserved patient population, rapidly expanding cardiac care capacity, and increasing domestic medical device innovation. India's National Health Mission and Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) program, the world's largest government-funded health insurance scheme, is progressively extending coverage for cardiac procedures to lower-income populations, expanding the addressable market beyond urban tertiary centers.
Additionally, India's trajectory is strongly upward, with rapidly increasing cardiac catheterization laboratory capacity, growing TAVR training programs across major hospital networks, and improving post-procedure outcomes reinforcing adoption among both high-risk and intermediate-risk patient cohorts.
The regions and countries of the market are as follows:
The market exhibits a consolidated competitive structure, with a small cluster of large multinational medical device companies commanding a dominant share of global revenues while a broader tier of regional and specialty players occupies defined niches across product types, geographies, and procedural channels. This structural concentration is reinforced by high regulatory hurdles, capital-intensive clinical trial requirements, and entrenched relationships between leading manufacturers and high-volume TAVR centers that create significant switching costs. These barriers collectively make meaningful new entry into the TAVR segment exceptionally difficult, reinforcing the durability of incumbents' competitive positions over the forecast horizon. Additionally, domestically focused innovators in select high-growth markets are increasing regional competition, though their influence remains limited relative to the dominant global manufacturers.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages